Benazepril

CAS: 86541-75-5

Rif. 3D-FB171048

Informazioni sul prodotto

• Nome: Benazepril
• Sinonimi: (3S)-3-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid, 1H-1-Benzazepine-1-acetic acid, 3-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)-, 1H-1-Benzazepine-1-acetic acid, 3-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-, [R-(R*,R*)]-, 1H-1-Benzazepine-1-acetic acid, 3-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-, [S-(R*,R*)]-, Benapril, Briem, Cibacen, Cibacen WS, Cibacene, [(3R)-3-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid
• CAS: 86541-75-5

Descrizione

Benazepril is a drug that is used to treat hypertension and congestive heart failure. It is also used in the treatment of renal disease, diabetic nephropathy, and post-myocardial infarction syndrome. Benazepril inhibits angiotensin I-converting enzyme (ACE), an enzyme involved in the conversion of angiotensin I to angiotensin II. This leads to decreased activity of the renin-angiotensin system, which results in reduced blood pressure and vasodilation. Benazepril has been shown to have beneficial effects on cardiac remodelling and fibrosis due to its ability to inhibit injury caused by growth factor-β1. The low dose group had better outcomes than the high dose group with respect to cardiac effects, such as papillary muscle thickening and tubulointerstitial injury. These effects were reversed following discontinuation of benazepril therapy.

• Marchio: Biosynth

Proprietà chimiche

• Peso molecolare: 424.49 g/mol
• Formula: C₂₄H₂₈N₂O₅
• Purezza: Min. 95%